Tadalafil for Sarcoidosis Associated Pulmonary Hypertension

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2013

Conditions
Pulmonary Hypertension
Interventions
DRUG

Tadalafil

20mg/day for one month then 40mg/day for additional 4 months

Trial Locations (2)

27599

University of North Carolina at Chapel Hill, Chapel Hill

45267

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

United Therapeutics

INDUSTRY

collaborator

University of Cincinnati

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT01324999 - Tadalafil for Sarcoidosis Associated Pulmonary Hypertension | Biotech Hunter | Biotech Hunter